Briefing on the Fundamentals of Tilray Brands (TLRY)

Tilray Brands moved -1.6% this morning session, trading between a high of $2.558 and a low of $2.5 per share. Yesterday the stock finished at $2.54 per share, compared to an average analyst target price of $None.

Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The small-cap biotechnology: pharmaceutical preparations company is based in Canada, and over the last twelve months it has returned a dividend yield of None%. Tilray Brands has trailing twelve months earnings per share (EPS) of -1.05, which at today's prices amounts to a price to earnings (P/E) ratio of -2.4.

Based on its expected future earnings growth, the company has a price to earnings growth (PEG) ratio of None. Usually a PEG ratio between zero and one indicates a potentially undervalued company.

TLRY has a revenue per share ratio of None and an enterprise value to revenue ratio of None, based on its total revenue of $628372000.0. The company's revenues have a year-on-year growth rate of None%, compared to a YoY growth rate of None% for its earnings.

Here's an overview of the company's gross margins in recent years:

Date Reported Revenue ($ k) Cost of Revenue ($ k) Gross Margins (%) YoY Growth (%)
2022-05-31 628,372 511,555 18.59 -22.57
2021-05-31 513,085 389,903 24.01 -31.81
2020-05-31 390,996 253,314 35.21 10.69
2019-05-31 175,248 119,504 31.81 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.